Apollon Formularies plc Apollon CEO Keynote speaker at Cannabis Conference
September 05 2022 - 2:00AM
RNS Non-Regulatory
TIDMAPOL
Apollon Formularies plc
05 September 2022
5 September 2022
Apollon Formularies Plc
Chairman and CEO of Apollon is a Keynote speaker at the Cannabis
Science Conference in Baltimore
Apollon Formularies plc (AQSE: APOL, "Apollon" or the
"Company"), a UK-based international pharmaceutical company trading
on the Aquis Stock Exchange, is pleased to announce that Dr.
Stephen Barnhill, Chairman and CEO of Apollon, is an invited
keynote speaker at the Cannabis Science Conference ("CSC"), being
held in Baltimore on 14-16 September 2022. Dr. Barnhill will
deliver a presentation on the "Unique Combination of Cannabis and
Mushrooms for the Treatment of Cancer" at 3:40 pm EDT/20:40 pm BST
on 15 September.
CSC is the world's largest and fastest growing cannabis science
event with a specialised focus on medical cannabis, analytical
science, cultivation science, psychedelic science, hemp, and CBD.
The conferences bring together a wide range of experts within the
cannabis industry, including research scientists, medical
practitioners, policy makers, instrument manufacturers and testing
labs. The event aims to improve cannabis science and education. No
new information related to Apollon will be released during the
session.
Stephen Barnhill , MD, Chairman and CEO of Apollon Formularies
plc , stated: "I am honoured to have been invited to address the
upcoming Cannabis Science Conference, a world-leading medical
cannabis event. It will serve as an opportunity to showcase
Apollon's compelling third-party testing results which showed its
proprietary medical cannabis formulations successfully killing
nearly 100% of prostate, triple negative and HER2+ breast cancer
cells in 3D cell cultures. This endorsement by CSC is significant
for Apollon, as it further strengthens our credibility and will
improve our visibility, particularly in North America."
Interested parties can register for the event via the website:
www.cannabisscienceconference.com
- Ends -
For additional information, please visit www.apollon.org.uk or
contact:
Apollon Formularies
Tel: +44 771 198 0221
Stene Jacobs stene@apollon.org.uk
BlytheRay (Financial PR/IR-London)
Tel: +44 207 138 3204
Tim Blythe/Megan Ray apollon@blytheray.com
About Apollon Formularies and Apollon Formularies Jamaica
Apollon Formularies plc is an international medical cannabis and
medicinal mushroom pharmaceutical company headquartered in the
United Kingdom. Apollon Formularies Jamaica Limited is a
pharmaceutical company incorporated and operating in the
Commonwealth of Jamaica since 2016. Apollon Jamaica is licensed by
the Jamaican government's Cannabis Licensing Authority (CLA) to
cultivate (R&D), perform research and development, process, and
sell medical cannabis therapeutic products that include legal
medical cannabis to treat various illnesses under medical
supervision.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRALIMMTMTJMTLT
(END) Dow Jones Newswires
September 05, 2022 02:00 ET (06:00 GMT)
Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From Apr 2024 to May 2024
Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From May 2023 to May 2024